loading...| Preferred Name |
Temozolomide |
|
| Synonyms |
3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide M and B 39831 TEMOZOLOMIDE M & B 39831 Methazolastone Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one temozolomide imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- Temozolomide CCRG-81045 Gliotem RP-46161 SCH 52365 TMZ Temcad Temizole Temodal Temodar Temomedac |
|
| Definitions |
A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1244 |
|
| Accepted_Therapeutic_Use_For |
Malignant glioma (Anaplastic astrocytoma; Anaplastic oligodendrogliomas; Anaplastic oligoastrocytomas; Glioblastoma multiforme); Metastatic melanoma |
|
| ALT_DEFINITION |
A drug that is used to treat certain types of brain tumors in adults and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called alkylating agents. |
|
| CAS_Registry |
85622-93-1 |
|
| Chemical_Formula |
C6H6N6O2 |
|
| code |
C1244 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04) |
|
| Display_Name |
Temozolomide |
|
| FDA_UNII_Code |
YF1K15M17Y |
|
| FULL_SYN |
3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide M and B 39831 TEMOZOLOMIDE M & B 39831 Methazolastone Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one temozolomide imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- Temozolomide CCRG-81045 Gliotem RP-46161 SCH 52365 TMZ Temcad Temizole Temodal Temodar Temomedac |
|
| Is_Value_For_GDC_Property | ||
| label |
Temozolomide |
|
| Legacy Concept Name |
Temozolomide |
|
| Maps_To |
Temozolomide |
|
| NCI_Drug_Dictionary_ID |
41671 |
|
| NSC Number |
362856 |
|
| PDQ_Closed_Trial_Search_ID |
41671 |
|
| PDQ_Open_Trial_Search_ID |
41671 |
|
| Preferred_Name |
Temozolomide |
|
| prefixIRI |
Thesaurus:C1244 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0076080 |
|
| subClassOf |